|
2024 Conference Publication Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitisHuynh, David, Khaing, Myat, Fernandes, Richard, Malloy, Reuben, Lin, Lei, Gilmore, Robert, Walker, Nicole, Khoo, Emi and Begun, Jakob (2024). Upadacitinib was administered as a sequential salvage therapy for acute severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2022, Sydney, NSW Australia, 9 - 11 September 2022. Richmond, VIC Australia: John Wiley & Sons. doi: 10.1111/jgh.16702 |
|
2024 Conference Publication Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of conceptGiri, Rabina, Amiss, Anna, Riches, Bruce, Carpinelli De Jesus, Matheus and Begun, Jakob (2024). Topical upadacitinib is effective in distal ulcerative colitis: A case study and pre-clinical proof of concept. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2024, Adelaide, SA Australia, 14-16 September 2024. Richmond, VIC Australia: John Wiley & Sons. |
|
2024 Conference Publication Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisKhoo, Emi, Amiss, Anna, Ding, Nik S., Bryant, Robert V., Mohsen, Waled, Connor, Susan J., Leong, Rupert, Croft, Anthony, Lynch, Kate D., Sparrow, Miles, De Cruz, Peter, An, Yoon-Kyo, Holtmann, Gerald J. and Begun, Jakob (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Digestive Disease Week (DDW) 2024, Washington, DC, United States, 18-21 May 2024. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(24)00988-0 |
|
2024 Conference Publication A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient SatisfactionFernandes, Richard G., Khoo, Emi, Harris, Heidi Jensen, Gilmore, Robert, Khaing, Myat Myat, Begun, Jakob and An, Yoon-Kyo (2024). A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)01652-4 |
|
2024 Conference Publication Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights ProgramMcNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Ng, Watson, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Andrews, Jane M. and Connor, Susan J. (2024). Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)02405-3 |
|
2024 Conference Publication The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's ProgramPipicella, Joseph L., McNamara, Jack, Wilson, William E., Lynch, Kate D., Walker, Gareth J., Begun, Jakob, Lawrance, Ian C., Ghaly, Simon, Radford-Smith, Graham L., Williams, Astrid-Jane, Gearry, Richard, Schultz, Michael, Brett, Laurel, Andrews, Jane M. and Connor, Susan J. (2024). The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03792-2 |
|
2024 Conference Publication Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights ProgramAlshiwanna, Basheer, McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Williams, Astrid-Jane, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Connor, Susan J. and Andrews, Jane M. (2024). Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03074-9 |
|
2024 Conference Publication Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights ProgramBarnett, Meghan I., McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Williams, Astrid-Jane, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Connor, Susan J. and Andrews, Jane M. (2024). Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03072-5 |
|
2024 Conference Publication Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitisKhoo, E., Amiss, A., Ding, J. N., Bryant, R., Mohsen, W., Connor, S., Leung, R., Croft, A., Lynch, K., Sparrow, M., De Cruz, P., An, Y. K., Holtmann, G. and Begun, J. (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0984 |
|
2024 Conference Publication Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration studyKim, S. J., Kim, D. H., Park, S. H., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Risk of Infection After Acute Severe Ulcerative Colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0892 |
|
2024 Conference Publication Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to TofacitinibGilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugpal, K., Han, S., Bryant, R., West, J., Segal, J., Christensen, B., Ding, N. J., An, Y. K. and Begun, J. (2024). Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1194 |
|
2024 Conference Publication A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfactionFernandes, R., Khoo, E., Harris, H., Gilmore, R., Khaing, M., Begun, J., An, Y. K. and Mater IBD Research Group (2024). A cost-effective Inflammatory Bowel Disease flare management pathway utilising rapid access intestinal ultrasound and nurse-led triage to achieve hospital avoidance with increased patient satisfaction. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0750 |
|
2024 Conference Publication Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trialDavies, J., Amiss, A., Khoo, E., An, Y. K. and Begun, J. (2024). Peripheral immune cell activity and biopsy gene expression in chronic pouchitis patients treated with tofacitinib: early induction results from the STOPit trial. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0164 |
|
2024 Conference Publication Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration studyKim, D. H., Park, S. H., Kim, H. S., Kim, S. J., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0555 |
|
2023 Conference Publication Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitisGilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugopal, K., Han, S., Bryant, R., Corte, C., Ding, J. N., An, Y-K and Begun, J. (2023). Australian multicenter real-world experience of upadacitinib induction therapy for moderate to severe ulcerative colitis. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portalMcnamara, J., Pipicella, J., Ghaly, S., Gearry, R., Forbes, A., Begun, J., Wark, G., Lynch, K., Lawrence, I., Schultz, M., Walker, G., Radford-Smith, G., Brett, L., Verdon, C., Andrews, J. and Connor, S. (2023). The evolving role of technology in delivering consumer-centric care for inflammatory bowel disease: An Australasian experience with Crohn's Colitis Care's e-health consumer portal. HOBOKEN: WILEY. |
|
2023 Conference Publication Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease studyEtchegaray, A., Fernandes, R., Anandan, A. Shanmuga, Selvanathan, P., Malloy, R., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Real-world study finds similar effectiveness of biologics but higher durability of ustekinumab in patients with Crohn's disease: Preliminary results from the COMPARE-IT Crohn's disease study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Australian consensus on ustekinumab in Crohn's diseaseBegun, J., An, Y-K, Bryant, R., Christensen, B., Leong, R., Studd, C. and Thin, L. (2023). Australian consensus on ustekinumab in Crohn's disease. HOBOKEN: WILEY. |
|
2023 Conference Publication Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasoundFernandes, R., Harris, H., Khoo, E., Gilmore, R., Howlett, M., Walker, N., Hendy, P., Begun, J. and An, Y-K (2023). Reducing hospital resource utilization and improving patient satisfaction with an innovative inflammatory bowel disease nurse-led clinical care pathway with rapid-access intestinal ultrasound. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2—5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
|
2023 Conference Publication Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT studyAnandan, A. Shanmuga, Fernandes, R., Etchegaray, A., Malloy, R., Selvanathan, P., Gilmore, R., Pham, H., Begun, J. and An, Y-K (2023). Vedolizumab has longer persistence than infliximab for ulcerative colitis in a real-world cohort study: Preliminary results from the COMPARE-IT study. Gastroenterological Society of Australia (GESA) Australian Gastroenterology Week (AGW) 2023, Brisbane, QLD Australia, 2-5 September 2023. Richmond, VIC Australia: John Wiley & Sons. |
